尼麦角林治疗血管性痴呆优于吡拉西坦

Nicergoline is better than piracetam in treating vascular dementia

目的：比较尼麦角林与吡拉西坦对血管性痴呆的疗效。方法：８０例血管性痴呆病人随机分为２组。尼麦角林组４２例（男性２８例，女性１４例，年龄６８±ｓ７ａ），服用尼麦角林片１０ｍｇ，ｔｉｄ，治疗８ｗｋ。吡拉西坦组３８例（男性２６例，女性１２例，年龄６９±８ａ），服用吡拉西坦１．２ｇ，ｔｉｄ，治疗８ｗｋ。结果：尼麦角林组总有效率为７９％，吡拉西坦组为５５％（Ｐ＜０．０５）；记忆商数（ＭＱ）和长谷川痴呆量分（ＨＤＳ）尼麦角林组分别增值１２±１１分和７±６分，吡拉西坦组分别增值５±８分和４±４分，２组间比较Ｐ＜０．０５，未见不良反应。

AIM: To compare the therapeutic effects of nicergoline and piracetam on vascular dementia. METHODS: The 80 patients with vascular dementia were randomly divided into 2 groups. Nicergoline group of 42 patients (M 28,F14,age 68±s 7 a) received nicergoline 10 mg, po, tid, for 8 wk. Piracetam group of 38 patients (M 26, F 12, age 68±8 a) received piracetam 1.2 g, po, tid, for 8 wk. RESULTS:The total effective rates were 79% in nicergoline group and 55% in piracetam group(P<0.05).The memory quotient(MQ) and HDS (Hastgawa Dementia scale) in nicergoline group were 12±11 and 7±6, respectively, in piracetam group were 5±8 and 4±4, respectively (P<0.05).No adverse reactions were found.CONCLUSION: The therapeutic effects of nicergoline is superior to piracetam in treating vascular dementia.